AnalystsInsight

Sam Slutsky (LifeSci Capital): Analyst Track Record and Price‑Target Accuracy

How often Sam Slutsky’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 1,145 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

Key takeaways

  • Sam Slutsky ranks #116 of 1,000 analysts in Exent’s scoring (5.0★).
  • 27.5% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 102 days; 38.8% of calls were up 12 months later.
  • Most‑covered stocks: SYRE, OLMA, PVLA, ABVX.

Sam Slutsky’s track record at a glance

Sam Slutsky of LifeSci Capital ranks #116 of the 1,000 analysts Exent scores, with a 5.0★ rating and a focus on healthcare. Over a 7‑year lookback, 27.5% of Sam’s price targets were reached, 24.9 points below the 52.4% average across all analysts.

MetricSam SlutskyAll analysts
Price‑target hit rate27.5%52.4%
Median days to hit target102 days91 days
Calls up after 12 months38.8%64.0%
Median 12‑month return of calls−20.3%+13.4%
Hit rate, last 2 years27.3%—
Average worst drop after a call−35.4%—
Ratings in the sample1,145—
Stocks covered22—

How fast price targets were reached

Time to reach the targetSam Slutsky
Under 30 days17.9%
30–90 days26.9%
90–180 days26.1%
Over 180 days29.1%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Sam Slutsky covers most

StockRatings in the sample
SYRE41
OLMA32
PVLA32
ABVX32
ELVN26
ORKA24
COGT20
AVBP19

In the past year Sam’s ratings were 95% Buy, 5% Hold and 0% Sell.

Recent ratings (shown with a 30-day delay)

DateStockActionRatingPrice target
Sep 19, 2026OLMAReiterated: BuyBuy$16.00
Sep 18, 2026DMRAReiterated: BuyBuy$45.00
Sep 16, 2026PYXSReiterated: BuyBuy$6.00
Sep 15, 2026COGTReiterated: BuyBuy$55.00
Sep 14, 2026OLMAReiterated: BuyBuy$16.00
Sep 14, 2026AVBPReiterated: BuyBuy$43.00
Sep 11, 2026IMUXReiterated: BuyBuy$56.00
Sep 9, 2026ORKAReiterated: BuyBuy$175.00
Sep 9, 2026PYXSReiterated: BuyBuy$6.00
Sep 8, 2026SYREReiterated: BuyBuy$116.00
Sep 5, 2026ATTOReiterated: BuyBuy$45.00
Sep 2, 2026TCRXDowngraded: HoldHold$0.00
  • Sep 19, 2026
    Stock
    OLMA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $16.00
  • Sep 18, 2026
    Stock
    DMRA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $45.00
  • Sep 16, 2026
    Stock
    PYXS
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $6.00
  • Sep 15, 2026
    Stock
    COGT
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $55.00
  • Sep 14, 2026
    Stock
    OLMA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $16.00
  • Sep 14, 2026
    Stock
    AVBP
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $43.00
  • Sep 11, 2026
    Stock
    IMUX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $56.00
  • Sep 9, 2026
    Stock
    ORKA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $175.00
  • Sep 9, 2026
    Stock
    PYXS
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $6.00
  • Sep 8, 2026
    Stock
    SYRE
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $116.00
  • Sep 5, 2026
    Stock
    ATTO
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $45.00
  • Sep 2, 2026
    Stock
    TCRX
    Action
    Downgraded: Hold
    Rating
    Hold
    Price target
    $0.00

Live ratings from Sam Slutsky and the other top‑ranked analysts, and the stocks where they agree, are in Exent Stocks Radar.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 19, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Stocks Radar shows Sam Slutsky’s live ratings and those of the other top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Sam Slutsky ranks #116 of 1,000 with a 5.0★ rating. 27.5% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 38.8% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Sam Slutsky’s success rate is 49.8% by the ranking source and 27.5% by Exent’s price-target hit-rate backtest, with a median of 102 days to reach a target.

Sam Slutsky (LifeSci Capital) covers 22 stocks, mostly in healthcare. The most frequently rated are SYRE, OLMA, PVLA, ABVX, ELVN.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.